PORTLAND, Ore., April 16, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, "Emphysema Treatment Market by Treatment Type (Medication, Oxygen Therapy, and Surgery), Type (Centriacinar, Panacinar, and Others), End User (Hospitals, Homecare, Specialty Centres, and Others): Global Opportunity Analysis and Industry Forecast, 2023-2032." According to the report, the emphysema treatment market was valued at $6.3 billion in 2022, and is estimated to reach $8.7 billion by 2032, growing at a CAGR of 3.3% from 2023 to 2032.
Request Sample of the Report on Emphysema Treatment Market Forecast - https://www.alliedmarketresearch.com/request-sample/A14372
Prime Determinants of Growth
The emphysema treatment market has experienced significant growth owing to rise in prevalence of emphysema cases globally. Furthermore, rise in number of smokers has contributed in the increasing prevalence of emphysema. In addition, Asia-Pacific is expected to present significant opportunities for growth owing to rise in awareness programs for emphysema, increasing diagnosis and increase in investments for well-developed healthcare infrastructure.
Report coverage & details
Report Coverage | Details |
Forecast Period | 2022-2032 |
Base Year | 2022 |
Market Size in 2022 | $6.30 Billion |
Market Size in 2032 | $8.73 Billion |
CAGR | 3.3 % |
No. of Pages in Report | 321 |
Segments covered | Treatment Type, Type, End User, and Region |
Regional scope | North America, Europe, Asia-Pacific and LAMEA |
Country scope | U.S., Canada, Mexico; France, Germany, Italy, Spain, UK, Rest of Europe China, Japan, India, South Korea, Australia, Rest of Asia-Pacific Brazil, South Africa, Saudi Arabia, and rest of LAMEA |
Drivers | Increase in prevalence of emphysema cases |
Surge in number of smokers globally | |
Increase in air pollution contributing to emphysema | |
Opportunity | Side effects associated with medications |
Restraint | High cost of treatment |
2023 Recession Impact Analysis
The global recession has significant impact on emphysema treatment market. The economic instability has had adverse effects on fresh investments and funding allocated to R&D activities for developing new & advanced emphysema treatment options. In addition, financial strain has led to reductions in budgets for hospital management.
However, the market for emphysema treatment is expected to recover owing to rise in prevalence of emphysema.
Want to Explore More, Connect to our Analyst- https://www.alliedmarketresearch.com/connect-to-analyst/A14372
The medication segment to maintain its leadership status throughout the forecast period
Depending on treatment type, the medication segment held the highest market share in 2022, accounting for almost three-fourths of the market revenue, owing to high adoption of the medications such as bronchodilators and steroids for treatment of emphysema. In addition, easy availability and cost-effectivity of the medication contribute toward high adoption of the medications.
The centriacinar segment to maintain its leadership status throughout the forecast period
By type, the centriacinar segment held the highest market share in 2022, accounting for almost half of market revenue, owing to high prevalence of centriacinar emphysema. In addition, rise in number of smokers globally has contributed significantly in the rising prevalence of centriacinar emphysema.
The homecare segment to maintain its leadership status throughout the forecast period
On the basis of end user, the homecare segment held the highest market share in 2022, accounting for more than two-fifths of the emphysema treatment market revenue, owing to rising trend toward home healthcare. In addition, the development of portable oxygen therapy has contributed toward the growth of the segment.
For Purchase Inquiry - https://www.alliedmarketresearch.com/purchase-enquiry/A14372
North America to maintain its leadership status throughout the forecast period
Region wise, North America held the highest market share in 2022, accounting for two-fifths of emphysema treatment market revenue. This is attributed to surge in R&D activities, well-developed healthcare infrastructure, and rise in prevalence of emphysema.
However, Asia-Pacific is expected to register a noteworthy CAGR during the forecast period, owing to decreasing air quality index, initiatives for early diagnosis, and increasing healthcare investments.
Leading Market Players
- Astrazeneca
- Boehringer Ingelheim International GmbH
- Glaxosmithkline Plc.
- Viatris Inc.
- Novartis Ag
- Orion Corporation
- Teva Pharmaceutical Industries Ltd.
- Verona Pharma Plc.
- Koninklijke Philips N.V.
- Inogen Inc.
The report provides a detailed analysis of these key players in the emphysema treatment market. These players have adopted different strategies such as acquisition, agreement, investment, product launch, product approval, and clinical trials to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int'l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on: LinkedIn
Twitter
Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/emphysema-treatment-market-to-reach-8-7-billion-globally-by-2032-at-3-3-cagr-allied-market-research-302118056.html
